Early CD8 T-cell memory precursors and terminal effectors exhibit equipotent in vivo degranulation

Yevgeniy Yuzefpolskiy, Florian M. Baumann, Vandana Kalia and Surojit Sarkar

Early after priming, effector CD8 T cells are distinguished into memory precursor and short-lived effector cell subsets (MPECs and SLECs). Here, we delineated a distinct in vivo heterogeneity in killer cell lectin-like receptor G1 (KLRG-1) expression, which was strongly associated with diverse MPEC and SLEC fates. These in vivo MPECs and SLECs expressed equivalent levels of cytotoxic molecules and effector cytokines. Using a unique in vivo degranulation assay, we found that the MPECs and SLECs similarly encountered infected target cells and elaborated equivalent levels of cytotoxicity in vivo.

These data provide direct in vivo evidence that memory-fated cells pass through a robust effector phase. Additionally, the preferential localization of the MPECs in the lymph nodes, where a lesser degree of cytotoxicity was elaborated, suggests that the MPECs may be protected from excessive stimulation and terminal differentiation by virtue of their differential tissue localization. These data provide novel mechanistic insights into the linear decreasing potential model of memory differentiation.

INTRODUCTION

During viral infections, naive CD8 T cells rapidly proliferate and differentiate into effector cells upon receiving optimal T cell receptor, costimulatory and inflammatory signals.1–4 Once they mediate pathogen clearance, the majority (90%–95%) of the effector cells die via apoptosis (referred to as short-lived effector cells, SLECs) and only a small subset survives (referred to as memory precursor effector cells, MPECs) to form a pool of long-lived memory cells. It is now well established that the precursors of memory cells are generated during the effector expansion phase, and the identification of distinct surface markers that preferentially associate with SLEC or MPEC subsets in early effector cells has seen tremendous advancements during the last decade.5–9 We and others have shown that ex vivo heterogeneity in the killer cell lectin-like receptor G1 (KLRG-1) marks the MPEC and SLEC subsets during the early stages of T-cell expansion (approximately day 4 post-infection and onwards) following a viral infection: KLRG-1int cells represent the MPECs and KLRG-1hi cells represent the SLEC population.6,9 This clear distinction of terminal effector and memory fates has enabled further insights into the mechanisms regulating effector and memory lineage decisions.

There is considerable interest in the field towards understanding the cytotoxic history of the MPEC and SLEC subsets.10 Two models of memory differentiation are currently prevalent: the linear differentiation model, which posits that memory cells pass through an effector phase and the divergent model, which proposes that terminal effector and memory lineages are distinct and are dictated by distinct instructional cues.11 Effector CD8 T cells (or cytotoxic T lymphocytes, CTLs) kill infected target cells when they engage with a cognate peptide–MHC-I complex on the surface of the infected cells. Targeted cell killing is mediated by the release of cytotoxic granules (containing effector molecules, such as granzyme B and perforin)12 from lysosomal compartments of effector CD8 T cells, a process known as degranulation.13 During the process of degranulation, the lysosomal membrane proteins are transiently translocated to the surface of the CTLs. Hence, the CTLs that have recently degranulated are marked by the cell surface expression of lysosome associated membrane protein-1 (LAMP-1) and LAMP-2 proteins.14,15 Degranulation has been
shown to be a direct measure of killing by CTLs and is considered a more sensitive readout of CTL function. Several studies have measured the cytotoxic capabilities of MPECs and SLECs ex vivo and have contended that the memory cells pass through a robust effector stage. In fact, activation of the effector differentiation program has been linked to CD8 T-cell priming and proliferation. However, whether MPECs and SLECs elaborate similar levels of cytotoxicity in vivo remains to be investigated. Based on the differential anatomical localization of MPECs and SLECs, it is believed that specialized microenvironments within tissues may deliver differential signals, such as IL-2, IL-12, antigens, etc., and thereby, may imprint different levels of effector differentiation and memory potential in these subsets. In this study, we sought to directly compare the in vivo cytotoxic potential of MPECs and SLECs in their physiologically relevant, native infected environment.

To accomplish this goal, we used in vivo staining of KLRG-1, LAMP-1 (CD107a) and LAMP-2 (CD107b) proteins to distinguish between MPECs and SLECs in vivo while simultaneously measuring their degranulation potential during murine infection with lymphocytic choriomeningitis virus (LCMV). Our studies showed that KLRG-1 heterogeneity is distinguishable in vivo both lymphoid and non-lymphoid tissues and clearly marks the distinct MPEC and SLEC fates. Importantly, in vivo degranulation assessments have revealed that MPECs and SLECs possess similar degranulation potencies and mediate the antigen-specific release of cytotoxic granules only in the presence of cognate antigens. Interestingly, lesser degranulation occurred in the lymphoid tissues, where the MPECs preferentially localized, compared to the non-lymphoid tissues. These studies suggest that MPECs and SLECs differentiate into cytotoxic effectors similarly in vivo and that the extent of their cytotoxicity is location-dependent. These findings provide direct in vivo evidence in support of the linear naive to effector to memory differentiation model, with increased stimulation leading to decreased memory potential.

MATERIALS AND METHODS

Mice

C57BL/6 mice (Thy1.2+) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Thy1.1 P14 mice bearing the DGP33-specific T cell receptor were fully backcrossed to C57BL/6 mice and were maintained in our animal colony. All of the animals were used in accordance with the University Institutional Animal Care and Use Committee guidelines.

Virus and infections

The Armstrong strain of LCMV was propagated, titered and used as previously described. The mice were directly infected with 2 × 105 pfu of LCMV intraperitoneally, and the viral loads were determined at the indicated times as described previously.

Antibodies, in vivo KLRG-1 staining and flow cytometry

All of the antibodies were purchased from Biolegend (San Diego, CA, USA) with the exception of CD107b PE (clone ABL-93), which was procured from Santa Cruz Biotechnology. Anti-CD107a PE (clone 1D4B) and CD107b PE antibodies were used together in the presence of monensin to measure the in vivo degranulation. For the in vivo staining of KLRG-1 and CD27, 50 μg of each antibody was administered intravenously, and the lymphocytes were isolated from the indicated tissues 2 h later. The cells were then stained with CD8 and Thy1.1 antibodies and fixed with paraformaldehyde prior to the analysis by flow cytometry. For the analysis of the intracellular cytokines, 106 lymphocytes were stimulated with 0.2 μg/ml of GP33-41 peptide in the presence of brefeldin A for 5 h, followed by surface staining for CD8 and Ly5.1 and intracellular staining for interferon (IFN)-γ, tumor-necrosis factor (TNF)-α or IL-2. The ex vivo staining of the cells for surface or intracellular proteins and cytokines was conducted as previously described.

For the isolation of day 4.5 MPECs and SLECs, P14 chimeric mice containing 1 × 105 naïve antigen-specific CD8 T cells were infected with LCMV. The donor cells were distinguished in the recipient C57Bl/6 mice by expression of the congenic marker Thy1.1. The MPECs and SLECs were FACs purified using KLRG-1 as a distinguishing marker as described previously. Following FACs purification, approximately 1 × 106 purified KLRG-1hi and KLRG-1int CD8 T cells were adoptively transferred into infection-matched mice and longitudinally followed in the blood.

In vivo degranulation assay

To measure the in vivo degranulation of MPECs and SLECs, C57Bl/6 mice that were infected with LCMV 4.5 or 8 days previously were injected with 50 μg each of CD107a/b PE (or the isotype control) and KLRG-1 APC antibodies along with 10 μg of monensin per mouse. One or two hours later, the mice were killed and stained ex vivo with CD8 and Thy1.1 gating antibodies. The paraformaldehyde fixed samples were analyzed with flow cytometry.

Statistical analysis

Paired or unpaired Student’s t-tests (two-tailed) were used as indicated to evaluate the differences between the sample mean values. All of the statistical analyses were performed using Prism 5, and the P values of statistical significance are depicted by an asterisk according to the Michelin guide scale: *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001, and P > 0.05 was considered not significant (ns).

RESULTS

Distinct in vivo heterogeneity in KLRG-1 expression on early effector CD8 T cells

Effecter CD8 T cells exhibit heterogeneity in the expression of cell surface markers, such as KLRG-1, IL-2Rα and IL-7Rα, during the activation and expansion phases. Differential expression of these proteins has been shown to distinguish between MPEC and SLEC subsets with divergent memory and terminal effector fates, respectively. To determine if heterogeneity in the expanding effector CD8 T-cell population is also distinguishable in vivo, we performed an in vivo staining of...
LCMV, lymphocytic choriomeningitis virus. CD8 and Thy1.1 and analyzed by flow cytometry. CD8 and Thy1.1 were lymphocytes were isolated from the indicated tissues, stained in vivo with LCMV. At 4.75 or 8 days after infection, mice were injected intravenously with 50 μg of CD27 PE or KLRG-1 APC antibodies. After 2 h, lymphocytes were isolated from the indicated tissues, stained ex vivo for CD8 and Thy1.1 and analyzed by flow cytometry. CD8 and Thy1.1 were used as gating markers. KLRG-1, killer cell lectin-like receptor G1; LCMV, lymphocytic choriomeningitis virus.

the cell surface markers KLRG-1 (typically associated with terminally differentiated CD8 T cells) and CD27 (typically expressed at higher levels on activated and memory cells) by the intravenous administration of fluorescently labeled antibodies (Figure 1) in LCMV-infected mice at 4.75 and 8 days after infection. Such in vivo delineation of heterogeneity in the expression of the markers associated with diverse cell fates would allow for the direct analysis of effector CD8 T-cell subsets in their native environment.

Consistent with previous ex vivo staining data,6,9 we found that antigen-specific effector CD8 T cells also showed an evident in vivo heterogeneity in the expression of KLRG-1 during early (day 4.75) and peak (day 8) expansion in both secondary lymphoid (spleen and lymph nodes) and non-lymphoid (liver) tissues. CD27 expression increased after activation and was uniformly high on the day 4.75 effectors (Figure 1). However, the KLRG-1hi effectors expressed lower levels of CD27 at 8 days after infection. Notably, the balance of KLRG-1int and KLRG-1hi effectors was distinctive in the lymph nodes, with the majority of the lymph node-derived effector cells binding lower levels of anti-KLRG-1 antibodies at both 4.5 and 8 days after infection (Figure 1). In each tissue analyzed, the proportions of the KLRG-1int and KLRG-1hi effector subsets were similar using both in vivo and ex vivo staining methods. Additionally, the mean fluorescence intensity (MFI) of the KLRG-1 antibody staining was also largely similar for both subsets in all of the tissues analyzed (Supplementary Figure 1). These data suggest that the decreased proportions of KLRG-1hi antigen-specific CD8 T cells observed in the lymph nodes using in vivo staining were apparently independent of the confounding issues related to reduced antibody access in the lymph nodes. Notably, the KLRG-1int antigen-specific CD8 T cells were enriched in the lymph nodes at all of the time points analyzed after infection (Supplementary Figure 2). Together, these data demonstrate an evident in vivo KLRG-1 heterogeneity in effector CD8 T cells during the early and late stages of expansion, with the lymph nodes being distinctly populated with putatively less differentiated KLRG-1int effector cells.

**In vivo heterogeneity of KLRG-1 distinguishes memory and terminal effector fates**

A higher KLRG-1 expression level in the direct ex vivo stains has typically been associated with more terminally differentiated cells, such that the differential expression of KLRG-1 marks the diverse memory and death fates of the effector CD8 T cells.6,9 We next assessed the fates associated with the in vivo stained KLRG-1int and KLRG-1hi effector cells. The in vivo stained effector CD8 T cells were FACS purified at day 4.5 after infection and were adoptively transferred into infection-matched recipient mice. Infection-matched congenically distinct mice were employed as recipients to ensure that the donor cells differentiated in similarly infected environments from where they were purified. The donor cells were followed longitudinally in the blood, and the final numbers were determined at memory. As shown in Figure 2a, both effector subsets continued to expand to similar extents after transfer and increased their numbers by approximately 10-fold until the peak of the effector responses. However, following antigen clearance, the KLRG-1int subset underwent a lesser degree of contraction and preferentially survived into the memory phase compared to the KLRG-1hi effectors. Following contraction, the final numbers of KLRG-1int donor cells were also significantly higher in all lymphoid and non-lymphoid tissues analyzed at memory (Figure 2b). At the peak of the donor cell expansion, neither subset of the unstained donor cells had any of the remaining original KLRG-1 antibody stain that was used for sorting (data not shown). Thus, the KLRG-1int and KLRG-1hi donors underwent contraction and began to exhibit survival differences >5 days after the adoptive transfer when no detectable cell surface bound antibodies remained, suggesting that the differences in cell survivability were likely independent of the differential levels of cell.
surface bound KLRG-1 antibodies used during FACS purification. Consistent with *ex vivo* studies, these data clearly demonstrate that *in vivo* effector cell heterogeneity in KLRG-1 expression marks distinct MPEC and SLEC fates.

**Similar expression of effector molecules in the *in vivo* stained MPECs and SLECs**

Having thus devised and validated a method of delineating MPECs and SLECs *in vivo*, we next sought to understand the differentiation paths of MPECs and SLECs *in vivo* in their native environment. Memory cells have been proposed to differentiate from less differentiated effector cells, or in cases to even bypass the effector differentiation stage. To compare the effector status of the *in vivo* stained MPECs and SLECs, we first measured the expression levels of the key effector molecule granzyme B and the effector cytokines IFN-γ and TNF-α. Both *in vivo* marked subsets expressed similar levels of the intracellular granzyme B (Figure 2c) directly *ex vivo*. Notably, MPECs and SLECs that were purified and stained *in vivo* also expressed similar levels of the effector cytokines IFN-γ and TNF-α, after

---

**Figure 2** *In vivo* stained KLRG-1 heterogeneous effectors represent the MPEC and SLEC populations that express similar levels of effector molecules. At day 4.75 after the LCMV infection, splenocytes were isolated from the P14 chimeric mice that had been stained for KLRG-1 PE *in vivo* as described in Figure 1. The CD8⁺ T cells were sorted into KLRG-1⁻ and KLRG-1⁺ subsets, and approximately 1 x 10⁶ donor cells were adoptively transferred into congenitally mismatched C57Bl/6 recipient mice that had been infected with LCMV 4.75 days earlier (infection-matched recipients). (a) Antigen-specific donor CD8 T cells were analyzed in the PBMCs of the recipient mice at the indicated days after the adoptive transfer and are presented as line graphs. The average ± s.e.m. values are plotted from two independent repeats. Unpaired Student’s *t*-tests were used for the analysis of statistical significance, and *P* < 0.001 is depicted by ***. (b) The KLRG-1⁻ and KLRG-1⁺ donor cells were enumerated in the indicated tissues at approximately day 50 after the adoptive transfer by a flow cytometry analysis of the CD8 Thyl.1⁺ T cells. The bar graphs show the average number of donor cells at memory ± s.e.m. Unpaired Student’s *t*-tests were used for the analysis of statistically significant differences between the KLRG-1⁻ and KLRG-1⁺ groups (***P* < 0.001). The *in vivo* stained effector CD8 T cells from the day 4.75 LCMV-infected P14 chimeric mice were FACS purified into KLRG-1⁻ and KLRG-1⁺ subsets. (c) The level of granzyme B expression in both subsets was assessed by *ex vivo* intracellular staining and a flow cytometry analysis. Histogram plots with the MFI of granzyme B expression are shown. (d) The purified effector subsets were also stimulated with 0.2 μg/ml of GP33-41 peptide for 5 h in the presence of brefeldin A, followed by intracellular cytokine staining for IFN-γ and TNF-α. The MFI of the indicated cytokines that were stained in both effector subsets are presented as bar graphs. FACS, fluorescence-activated cell sorting; KLRG-1, killer cell lectin-like receptor G1; LCMV, lymphocytic choriomeningitis virus; MFI, mean fluorescence intensity; MPEC, memory precursor effector cell; PBMC, peripheral blood mononuclear cell; SLEC, short-lived effector cell.
5 h of in vitro peptide stimulation, on a per cell basis (Figure 2d). These data indicate that both MPECs and SLECs express effector molecules similarly.

**MPECs and SLECs degranulate to a similar extent in vivo in an antigen-dependent manner**

To directly assess the in vivo cytotoxic functions of MPECs and SLECs, we employed a unique in vivo degranulation assay to measure the extent of cytotoxic granule release by the effector subsets in their native physiological environment. The assay involved direct in vivo administration of the KLRG-1 antibody to distinguish between the MPECs and SLECs, along with CD107a/b antibodies to determine the extent of degranulation (Figure 3). Optimal in vivo antibody staining with a good correlation with ex vivo staining required an incubation time of approximately 1 h for the antibodies to reach dynamic equilibrium following egress from the vasculature and accessibility of the target cells. Thus, in vivo degranulation was assessed

**Figure 3** The MPECs and SLECs degranulate to a similar extent in vivo, as determined by the presence of antigens. The KLRG-1

---

Yuzefpolskiy et al
using 1 h and 2 h incubation times. The CD107a/b staining was only seen when the antibodies were administered in vivo. Splenocytes isolated without the in vivo staining (isotype control) of CD107a/b did not exhibit positive staining when stained for CD107a/b directly ex vivo (Figure 3a). This lack of CD107a/b staining on the day 4.75 effectors ex vivo in the absence of restimulation indicated that this assay measures the degranulation of cells following in vivo antigen stimulation. Importantly, the level of CD107a/b staining following the in vivo administration of the antibodies, as assessed by MFI of the CD107a/b staining, was similar in both the MPECs and SLECs (Figure 3a). These data demonstrate that there is an equivalent antigenic encounter and elaboration of cytotoxic function by MPECs and SLECs in vivo.

To further investigate the role of antigen and to assess the antigenic encounter history of MPECs and SLECs in our in vivo degranulation experiments, we compared in vivo CD107a/b staining on days 4.75 (when the systemic antigen was present) and 8 after infection (when LCMV was largely cleared from the system). The extent of the in vivo degranulation was similar in

---

**Figure 4**  Effector CD8 T cells degranulate to a higher extent in non-lymphoid tissues than in lymphoid tissues. The in vivo degranulation of effector cells was compared at days 4.75 and 8 after LCMV infection in the lymph nodes, PBMCs and the liver. The mice were killed, their tissues were isolated and antigen-specific CD8 T cells were stained ex vivo for the gating markers CD8 and Thy1.1 at 1 h or 2 h after the in vivo injection of the CD107a/b and KLRG-1 antibodies. The level of degranulation was assessed using flow cytometry. Representative FACS plots from two independent experiments are presented. FACS, fluorescence-activated cell sorting; KLRG-1, killer cell lectin-like receptor G1; LCMV, lymphocytic choriomeningitis virus; MPEC, memory precursor effector cell; PBMC, peripheral blood mononuclear cell; SLEC, short-lived effector cell.
the 1 and 2 hour assay times (Figure 3b), indicating the rapid release of cytotoxic granules following an antigenic encounter by CTLs so that the maximal level of degranulation was achieved within 1 h. Notably, the day 4.75 effectors indeed degranulated more than the day 8 effectors, as determined by the MFI of the in vivo stained CD107a/b (Figure 3b). These differences in antigen encounters and CTL function at days 4.75 and 8 post-infection clearly correlated with the differential viral loads in the spleen (Figure 3c). Thus, the in vivo staining of CD107a/b in the MPECs and SLECs measures antigen-dependent cytotoxic granule release in the native environment and reveals evident similarities in their in vivo cytotoxic potential.

**CTLs degranulate more in non-lymphoid tissues than in lymphoid tissues**

The data presented in Figures 2 and 3 demonstrate that FACS purified in vivo stained KLRG-1int and KLRG-1hi antigen-specific CD8 T cells from the spleen possess diverse fates despite elaborating similar degranulation in response to antigenic stimulation in the spleen. Based on (i) the increased prevalence of KLRG-1int cells in the lymph nodes (Figure 1 and Supplementary Figures 1 and 2) at all time-points post-infection; (ii) the preferential localization of the KLRG-1int donors in the lymph nodes rather than the KLRG-1hi donor cells shortly after the adoptive transfer into infection-matched recipients; and (iii) previous reports that lymph node-derived effector CD8 T cells enter the memory pool more readily than spleen derived effectors, we next compared the in vivo degranulation of the MPECs and SLECs in lymph nodes and in peripheral sites, such as the liver. As observed in splenocytes (Figure 3), the day 4.75 effectors degranulated more than the day 8 effectors in all other tissue sites analyzed as well (Figure 4). Moreover, the degranulation readouts were largely similar at the 1 and 2 h assay times, as observed previously (Figure 3), indicating rapid degranulation after stimulation. Surprisingly, we found an evident difference in the level of effector cell degranulation in the lymphoid tissues compared to the non-lymphoid tissues (Figure 4). Both the day 4.75 and 8 effectors exhibited more degranulation in the liver than in the lymph nodes. In general, the viral loads in the inguinal lymph nodes were approximately 10-fold lower than in the liver after intra-peritoneal acute infection with LCMV at approximately day 4.5 after infection, and all of the tissues were largely cleared of plaqueable virus at day 8 after infection (Figure 4b). These data are consistent with the measurable differences in the in vivo antigenic encounters and degranulation between day 4.5 and day 8 after infection as well as the lesser degree of degranulation observed in the inguinal lymph node.

Overall, both MPECs and SLECs exhibited decreased degranulation at day 8 in all of the tissues analyzed. This correlated with LCMV loads several logs lower at day 8 compared to day 4.75 post-infection (Figure 4c). However, compared to day 4.75, when MPECs and SLECs exhibited similarly potent in vivo degranulation in all of the tissues analyzed (Figures 3 and 4), MPECs shut down their effector functions more effectively in the inguinal lymph nodes at day 8 post-infection. This may be related to a more rapid viral clearance from the inguinal lymph nodes compared to the liver or spleen. Indeed, as shown in Figure 4b, lower LCMV loads were observed in the inguinal lymph nodes compared to the liver at day 4.75 after infection. Nevertheless, measurable degranulation was still observed at day 8 in the liver and in PBMCs (Figure 4c), and MPECs had modestly more degranulation than SLECs. While these differences are subtle, they are indicative of the continued differentiation of the KLRG-1int effector cells into more terminally differentiated KLRG-1hi cells in peripheral sites due to residual antigen stimulation. Slightly lower levels of degranulation of SLECs may be related to a possible functional exhaustion of SLECs due to prolonged antigenic stimulation in the peripheral sites. Collectively, these data demonstrate an increased antigenic stimulation in the peripheral sites, thereby resulting in greater terminal effector differentiation.

**DISCUSSION**

Collectively, these data provide strong in vivo evidence of MPEC and SLEC heterogeneity and direct in vivo proof that memory cells pass through a potent effector phase in the presence of antigens. Whether differentiation through an effector phase is obligatory for the development of memory cells remains to be determined. Indeed, it has been proposed that differentiation through an effector phase may result in epigenetic changes at critical effector gene loci that allow memory cells to remain in a ‘poised’ state to react swiftly following a secondary antigenic encounter.

Effector differentiation is closely tied to CD8 T-cell proliferation after priming. Using a unique in vivo degranulation assay, we showed that MPECs and SLECs encounter antigens similarly in the spleen and are capable of exerting cytotoxicity similarly in vivo. Using an in vitro degranulation assay, Wolint et al. have previously reported a progressive increase in effector CTL degranulation with increasing duration of stimulation with a cognate peptide antigen so that the frequency of the degranulating cells doubled when the stimulation times were increased from 1 h to 2 h and reached maximal levels at approximately 5–6 h. In contrast, we observed rapid in vivo degranulation with maximal levels within 1 h after stimulation and with no significant increase in the extent of degranulation when the assay time was increased to 2 h. This may be related to a more efficient antigen presentation in vivo, potentially due to distinct inflammatory stimulation milieu. Moreover, these data indicate that a 1 h incubation time is sufficient for the antibodies to egress from the vasculature and to stain the cells in their microenvironmental niche in the non-lymphoid and secondary lymphoid tissues. Based on a recent report by Anderson et al., stating that perfusion is inefficient at removing blood-borne lymphocytes from non-lymphoid peripheral organs, such as the lungs, it is possible that in the case of the liver, our in vivo staining readouts are reflective of both intravascular and tissue-resident lymphocytes.

Together with tissue localization data, these studies indicate that despite possessing similar cytotoxic potentials, MPECs exert less cytotoxicity in vivo by virtue of preferential localization to
the secondary lymphoid tissues with relatively lower antigen levels. It is conceivable that memory-fated cells manage to escape rapid and recurring degranulation in vivo during an infection and hence emerge as a metabolically fit population that has conserved its resources to survive long-term. These conclusions are supported by previous studies proposing that MPECs shut down their effector functions more rapidly\(^1\)\(^2\)\(^3\) and that lymph node-derived effector cells preferentially enter the memory pool compared to spleen-derived effector cells.\(^4\)

Several studies have shown that CD8 T cells that are activated relatively later during an immune response are less stimulated and preferentially differentiate into memory cells.\(^5\)\(^6\)\(^7\) In contrast, we have shown that a prolonged antigenic stimulation leads to the generation of KLRG-1\(^{hi}\) SLECs.\(^8\) Our current findings of the preferential localization of SLECs in non-lymphoid sites suggest that SLECs putatively mount increased rounds of killing after continually encountering antigens in peripheral sites, thereby undergoing terminal differentiation. These findings lend support to the decreasing potential model of memory differentiation, which posits that the potential of effector cells to differentiate into memory cells decreases progressively with increasing antigenic stimulation. Our data suggest that the increased antigenic stimulation of effector cells in peripheral sites may be a means of driving terminal effector differentiation: KLRG-1\(^{int}\) effectors may be driven towards a KLRG-1\(^{hi}\) terminally differentiated state due to repetitive antigenic encounters in peripheral sites, such as the liver and lungs, and KLRG-1\(^{lo}\) cells may be driven towards functional exhaustion. These findings lay the groundwork for more detailed functional, phenotypic and microarray investigations into the putative functional exhaustion of KLRG-1\(^{lo}\) cells, possibly due to increased antigenic encounters and related proliferation during the late stages of infection. The rapid shutdown of effector functions by MPECs in the lymph nodes, but the prolonged degranulation of the KLRG-1\(^{int}\) cells at day 8 in the liver further suggests that the KLRG-1\(^{int}\) effector subsets in the liver may be compromised in their ability to contribute to the long-lived pool of memory cells compared to the KLRG-1\(^{lo}\) effector cells in the inguinal lymph nodes. Thus, by using a unique assay to measure the in vivo cytotoxicity of MPECs and SLECs, the current study provides insight into the mechanisms of CD8 T-cell memory differentiation. A clear understanding of the in vivo events regulating effector and memory lineages has a direct bearing on vaccine-induced immunological memory.

ACKNOWLEDGEMENTS

This work was supported in part by research funding from the Pennsylvania State University to SS and VK.

Supplementary Information accompanies the paper on Cellular & Molecular Immunology's website. (http://www.nature.com/cmi).

1 Kalia V, Sarkar S, Ahmed R. CD8 T-cell memory differentiation during acute and chronic viral infections. Adv Exp Med Biol 2010; 684: 79–95.
2 Arens R, Schoenberger SP. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol Rev 2010; 235: 190–205.
3 Belz GT, Kallies A. Effector and memory CD8\(^{+}\) T cell differentiation: toward a molecular understanding of fate determination. Curr Opin Immunol 2010; 22: 279–285.
4 Zhang N, Bevan MJ. CD8\(^{+}\) cells: foot soldiers of the immune system. Immunity 2011; 35: 161–168.
5 Huster KM, Busch V, Schiemann M, Linkemann K, Kerkesik KM, Wagner H et al. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8\(^{+}\) memory T cell subsets. Proc Natl Acad Sci USA 2004; 101: 5610–5615.
6 Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J et al. Inflammation directs memory precursor and short-lived effector CD8\(^{+}\) T cells via the graded expression of T-bet transcription factor. Immunity 2007; 27: 281–295.
7 Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Sunr CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003; 4: 1191–1198.
8 Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8\(^{+}\) T cells favors terminal-effector differentiation in vivo. Immunity 2010; 32: 91–103.
9 Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med 2008; 205: 625–640.
10 Lefrançois L, Obar JJ. Once a killer, always a killer: from cytotoxic T cell to memory cell. Immunol Rev 2010; 235: 206–218.
11 Kalia V, Sarkar S, Goutrey TS, Rouse BT, Ahmed R. Differentiation of memory B and T cells. Curr Opin Immunol 2006; 18: 255–264.
12 Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31–37.
13 Wolint P, Betts MR, Koup RA, Osenius A. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8\(^{+}\) T cells. J Exp Med 2004; 199: 925–936.
14 Krzewski K, Gil-Krzewska A, Nguyen V, Peruzzi G, Coligan JE. LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity. Blood 2013; 121: 4672–4683.
15 Liu D, Bryceson YT, Meckel T, Vasilier-Shamis G, Dustin ML, Long EO. Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses. Immunity 2009; 31: 99–109.
16 Aktaş E, Kucuksezgin UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol 2009; 254: 149–154.
17 Obar JJ, Jellison ER, Sheridan BS, Blair DA, Pham QM, Zickovich JM et al. Pathogen-induced inflammatory environment controls effector and memory CD8\(^{+}\) T cell differentiation. J Immunol 2011; 187: 4967–4978.
18 Obar JJ, Molloy MJ, Jellison ER, Stoklasa TA, Zhang W, Ushevorod EW et al. CD4\(^{+}\) T cell regulation of CD25 expression controls development of short-lived effector CD8\(^{+}\) T cells in primary and secondary responses. Proc Natl Acad Sci USA 2010; 107: 193–198.
19 Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010; 32: 79–90.
20 Bannard O, Kraman M, Fearon DT. Secondary replicative function of CD8\(^{+}\) T cells that had developed an effector phenotype. Science 2009; 323: 505–509.
21 Jacob J, Baltimore D. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature 1999; 399: 593–597.
22 Manjunath N, Shankar P, Wan J, Wenninger W, Crowley MA, Hieshima K et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest 2001; 108: 871–878.
23 Lauvau G, Vigh S, Kong P, Hong T, Kerkesik K, Serbina N et al. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 2001; 294: 1735–1739.
24 Kedzierska K, Stambas J, Jenkins MR, Keating R, Turner SJ, Doherty PC. Location rather than CD62L phenotype is critical in the early
establishment of influenza-specific CD8$^+$ T cell memory. *Proc Natl Acad Sci USA* 2007; **104**: 9782–9787.

25 Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ *et al*. Intravascular staining for discrimination of vascular and tissue leukocytes. *Nat Protoc* 2014; **9**: 209–222.

26 Anderson KG, Sung H, Skon CN, Lefrancois L, Deisinger A, Vezys V *et al*. Cutting edge: intravascular staining redefines lung CD8 T cell responses. *J Immunol* 2012; **189**: 2702–2706.

27 D’Souza WN, Hedrick SM. Cutting edge: latecomer CD8 T cells are imprinted with a unique differentiation program. *J Immunol* 2006; **177**: 777–781.

28 Sarkar S, Teichgraber V, Kalia V, Polley A, Masopust D, Harrington LE *et al*. Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. *J Immunol* 2007; **179**: 6704–6714.

29 van Faassen H, Saidanha M, Gilbertson D, Dudani R, Krishnan L, Sad S. Reducing the stimulation of CD8$^+$ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62L$^{hi}$CD44$^{lo}$) subset. *J Immunol* 2005; **174**: 5341–5350.